DUBLIN--(BUSINESS WIRE)--The "Biosimilars Market by Product, Manufacturing Type and by Disease - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
The global biosimilars market is expected to reach USD 23.63 Billion by 2023 from USD 5.95 Billion in 2018, at a CAGR of 31.7%. The market is segmented by product, type of manufacturing, disease, and region.
The products in biosimilars market include non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The non-glycosylated proteins segment accounted for the largest market share of the market in 2017, however recombinant glycosylated proteins are expected to hold the largest share of the market during the forecast period.
On the basis of type of manufacturing, the market is classified into in-house manufacturing and contract manufacturing. The in-house manufacturing segment accounted for the largest share in 2017. Many players in the biosimilars market prefer the in-house method of manufacturing as they can develop biosimilars in their own laboratories and this type of manufacturing eliminates shipping and delivery costs.
On the basis of diseases, the market is classified into oncology, chronic diseases, autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases, and other diseases. The blood disorder segment accounted for the largest share of the market in 2017. The rising incidence of blood disorders across the globe, low cost of biosimilars compared to biologics, and the rising pressure to reduce healthcare expenditure are major factors contributing to the growth of this segment.
Market Dynamics
Drivers
- Increasing Demand for Biosimilar Drugs Due to Their Cost-Effectiveness
- Rising Incidence of Chronic Diseases
- Strategic Collaborations Resulting in Enhanced Productivity and Clinical Trial Activities for Biosimilars
Restraints
- Complexities in Manufacturing
- Innovative Strategies By Biologic Drug Manufacturers
Opportunities
- Growth Opportunities in Emerging Markets
- New Indications and Patent Expiry of Biologic Products
Challenges
- Stringent Regulatory Requirements to Adversely Affect Investments in Biosimilars
Key Topics Covered
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Regulatory Outlook
7 Biosimilars Market, By Product
8 Biosimilars Market, By Type of Manufacturing
9 Biosimilars Market, By Disease
10 Biosimilars Market, By Region
11 Competitive Landscape
12 Company Profiles
- Amgen
- Biocon
- Celltrion
- Dr. Reddy's Laboratories
- Mylan
- Pfizer
- Samsung Biologics
- Sandoz
- Stada Arzneimittel AG
- Teva Pharmaceutical
For more information about this report visit https://www.researchandmarkets.com/research/tcftdx/biosimilars_23?w=4
